SCHEMBL3597891

SCHEMBL3597891

COC(=O)c1ccc(CBr)c(I)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 6/20 0.48
MAPT P10636 6/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
XDH P47989 1/20 0.47
MGLL Q99685 1/20 0.45
LMNA P02545 2/20 0.43
NOTUM Q6P988 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31291738 0.86 CA1 (0.50) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL27914915 0.86 CA1 (0.50) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL2065651 0.85 KDM4E (0.53) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL27928427 0.85 CA1 (0.49) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL1028046 0.84 CA1 (0.52) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL29559628 0.84 CA1 (0.52) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL3560840 0.84 CA12 (0.53) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL28806479 0.83 CA1 (0.52) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL15543465 0.83 CA1 (0.52) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL3564657 0.83 GABRA1 (0.41) KDM4EALDH1A1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025201504-A1 KAT6 INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 WO disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 US disclosed
EP-3083583-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF SAGIMET BIOSCIENCES INC (US) 2020-11-18 EP disclosed
EP-3083583-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF SAGIMET BIOSCIENCES INC (US) 2020-11-18 EP disclosed
EP-3256468-B1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2020-04-08 EP disclosed
CN-105884758-B Tricyclic compounds and their use in medicine 广东东阳光药业有限公司 2019-12-10 CN disclosed
CN-106061963-B Heterocyclic modulators of lipid synthesis and combinations thereof 3-V生物科学股份有限公司 2019-10-22 CN disclosed
EP-2870150-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3 V BIOSCIENCES INC (US) 2019-06-19 EP disclosed
EP-2870150-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3 V BIOSCIENCES INC (US) 2019-06-19 EP disclosed
US-10226449-B2 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V BIOSCIENCES, INC. (US) 2019-03-12 US disclosed
WO-2014008197-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2014-01-09 WO disclosed
US-20120309702-A1 DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 UNIVERSITY OF KANSAS (US) 2012-12-06 US disclosed
WO-2012162054-A1 DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 THE UNIVERSITY OF KANSAS (US) 2012-11-29 WO disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 US disclosed
US-20100009973-A1 Integrase Inhibitors 3 AVEXA LIMITED (AU) 2010-01-14 US disclosed
EP-2019827-A1 INTEGRASE INHIBITORS 3 Avexa Limited (AU) 2009-02-04 EP disclosed
WO-2007124546-A1 INTEGRASE INHIBITORS 3 AVEXA LIMITED (AU) 2007-11-08 WO disclosed
US-20050026929-A1 Novel phenyl derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-02-03 US disclosed
WO-2003090680-A2 NOVEL PHENYL DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A KDM4E 349/4885ALDH1A1 2832/4885MAPT 171/4885
US-20050026929-A1 Novel phenyl derivatives as inducers of apoptosis BAX, BAD, CASP3 KDM4E 1180/4885ALDH1A1 1781/4885MAPT 2332/4885
US-10226449-B2 Heterocyclic modulators of lipid synthesis and combinations thereof FASN, FADS1, COASY KDM4E 2053/4885ALDH1A1 959/4885MAPT 4003/4885
US-20120309702-A1 DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 HSP90AA1, HSP90AB1, HSP90B1 KDM4E 3445/4885ALDH1A1 2017/4885MAPT 1495/4885
US-20100009973-A1 Integrase Inhibitors 3 TYMP, IMPDH1, IMPDH2 KDM4E 1075/4885ALDH1A1 1001/4885MAPT 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.